Bladder Cancer Cells chromosome and gene anomaly detection probe (CEP3/CEP7 ; P16/CEP17)

Bladder Cancer Cells Chromosome and Gene Anomaly Probe Detection Kit  - 200µL/10 Tests

Bladder cancer develop and progress through a series of genetic alterations. Understanding of the genetic mechanisms which lead to malignant transformation gave rise to the development of various genetic mechanisms which lead to malignant transformation gave rise to the development of various genetic tools providing better ability of early detection and more accurate prognosis prediction.

Product Main Components

The kit consists of one of P16/CEP7 probes or CEP3/CEP17 CEP3/CEP7dual color probe

Intended Usage

Bladder cancer is the most common malignant tumor of the urinary system. In the course of bladder cancer development, the abnormal expression of the cancer cells chromosome karyotype is extremely complex. Studies have shown that a considerable number of nonrandom chromosomes number and structure aberrations occur in the development, staging, grading, and therapeutic response of bladder cancer. A large number of studies have shown that chromosomes 3, 7, 17, and 9p21 are aberrations main diagnostic marker of bladder cancer, and detecting these abnormal chromosomes has important significance in the diagnosis and prognosis of bladder cancer.

 The recurrence rate of bladder cancer patients is higher after treatment, therefore it should be monitored. Standard monitoring protocols include cystoscopy and urine exfoliated cells examination. Cystoscopy is invasive and has poor compliance. It is difficult to diagnose early superficial tumors, and 10%-30% is false negative. Although the urine exfoliated cells examination is not invasive, it has high sensitivity to high-grade tumor, but it has low sensitivity to low grade tumor. Therefore, finding an effective early detection method for bladder cancer recurrence is an urgent problem to be solved. A large number of reports have shown that urine exfoliated cells fluorescence in situ hybridization technology has the advantages of being non-invasive, sensitive and specificity, and the sensitivity increases with the increase of tumor staging stage, and is an ideal means for diagnosing and monitoring bladder cancer recurrence.

 This product uses urinary sediment cells from patients with suspected bladder cancer as a test object, and uses fluorescence in situ hybridization to detect loss of aneuploidy and p16 (9p21) on chromosomes 3, 7, 17 in exfoliated cells. It can be used as an auxiliary measure for the early diagnosis of bladder cancer and the recurrence of bladder cancer in the patients with hematuria.

Detection Principle

 The kit is based on fluorescence in situ hybridization and uses nucleic acids probe labeled with fluorescein. The target gene to be detected is homologous complementary to the nucleic acids probe used. Both are denatured, annealed, and renatured. A hybrid of the target gene and the nucleic acids probe is formed, and the qualitative, quantitative or relative positioning analysis of the gene to be measured under the microscope is performed by the fluorescence detection system.

This kit utilizes a Rhodamine fluorescein (RHO)-labeled orangecolored probe and a green fluorescein Isothiocyanate (FITC)-labeled green probe. The two probes can be bound to the target detection site by in situ hybridization. This kit provides two sets of probes (CEP3/CEP7, p16/CEP17). Under normal conditions, each set of probes is displayed as two orange red signals and two green signals under a fluorescence microscope. When there is a missing chromosome or gene in the target sequence, the green or orange signal decreases accordingly. Detection of 3, 7, 17 aneuploidy and deletion of p16 (9p21) by this method can be used as an auxiliary detection method for clinical diagnosis and postoperative recurrence of bladder cancer.